Results 171 to 180 of about 5,286 (232)

Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy. [PDF]

Ann Med Surg (Lond)
Hujjat SFZ, Chandani HK, Khan MS, Chandani DK, Mahmoud A.   +4 more
europepmc   +1 more source

Bruton's tyrosine kinase inhibitors in diffuse large B-cell lymphoma therapy: critical considerations and future innovations. [PDF]

J Transl Med
Lu C, Chen Q, Shen Y, Chen M, Xie Y, Wang C, Yu L.   +6 more
europepmc   +1 more source

Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors - systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Hematol
Buchrits S, Trieman G, Giladi O, Hofstetter L, Gurion R, Granot G, Shacham-Abulafia A, Raanani P, Gafter-Gvili A.   +8 more
europepmc   +1 more source

Expression of Bruton's Tyrosine Kinase Reflects Immune Cells Infiltration and Cell Proliferation in Breast Cancer. [PDF]

World J Oncol
AlRammah T, Wu R, Chida K, Kawashima K, Hakamada K, Ishikawa T, Ebos JML, Takabe K.   +7 more
europepmc   +1 more source

A Novel Dual Bruton's Tyrosine Kinase/Janus Kinase 3 Inhibitor Wj1113 and its Therapeutic Effects on Rheumatoid Arthritis. [PDF]

MedComm (2020)
Zhang C, Lai F, Gong H, Li S, Xiang N, Que L, Xue N, Hao M, Zhou E, Wang X, Liang T, Jin J.   +11 more
europepmc   +1 more source

Pharmacologic Inhibition of Bruton's Tyrosine Kinase Attenuates Experimental Abdominal Aortic Aneurysms

JVS - Vascular Science, 2020
Baohui Xu, Yankui Li, Gang Li, Yingbin Ge, Jia Guo, Weirong Fang, Wei Wang, Fanru Shen, Takahiro Shoji, Toru Ikezoe, Xiaoya Zheng, Sihai Zhao, Xiaofeng Chen, Masaaki Miyata, Alan Daugherty, Hong Lu, Ronald L. Dalman   +16 more
doaj   +1 more source

Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy. [PDF]

Front Oncol
Oura M, Toho M, Ikeda D, Fukuda N, Torres AS, Fujii F, Sakuma H, Uehara A, Tabata R, Narita K, Takeuchi M, Matsue K.   +11 more
europepmc   +1 more source

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. [PDF]

J Hematol Oncol
Dell'Aversana C, Sgueglia G, Massaro C, Perricone U, Sarno F, Megchelenbrink WL, Conte M, Carafa V, Campanella A, Frenquelli M, Bordini J, Ghia P, Petrizzi VB, Alvarez R, Nappi D, Chiurazzi F, Tambaro FP, Wierda WG, de Lera AR, Altucci L.   +19 more
europepmc   +1 more source

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source

Leveraging Kinase Drugs for Neurosciences: Discovery of Selective, CNS-Penetrant Reversible Bruton's Tyrosine Kinase Inhibitors as Therapeutics for Neuroinflammation. [PDF]

J Med Chem
Hopkins BT, Marx IE, Vandeveer HG, Nevalainen M, Basile R, Bajrami B, Choi CK, Grater RJ, Gu C, Hoemberger M, Kadakia E, Kapadnis SK, Liu Y, Ma B, Magee T, Metrick CM, Mingueneau M, Muste CA, Parker Harp CR, Prince RJ, Santoro JC, Schulz J, Sciabola S, Tang H, Wang T, Meissner R, Bohnert T.   +26 more
europepmc   +1 more source